D-1845-2019 Class II Terminated
FDA drug recall D-1845-2019 was initiated by Pfizer Inc. on Aug 14, 2019 and is designated Class II. Reason for recall: Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas. The recall status is terminated (terminated Jun 20, 2023). Affected quantity: a) 20,117 cartons; b) 2,502 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 4, 2019
- Initiation Date
- Aug 14, 2019
- Termination Date
- Jun 20, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 20,117 cartons; b) 2,502 cartons
Product description
RELPAX (eletriptan HBr) tablets, 40 mg, packaged in a) 6-count (1 card x 6 tablets) per carton, NDC 0049-2340-45; b) 12-count (2 cards x 6 tablets) per carton, NDC 0049-2340-05, Rx only, Made in Ireland, Distributed by Pfizer Roerig, Division of Pfizer Inc., NY, NY 10017.
Reason for recall
Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas.
Distribution pattern
Nationwide in the USA and Puerto Rico.
Code information
Lot #: a) AR5407, Exp 2022 FEB; b) CD4565, Exp 2022 FEB
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1845-2019
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.